Applied Genetic Tech (AGTC) Triggers Enrollment Milestone in XLRS Phase I/II; Roth Affirms at 'Buy'
Tweet Send to a Friend
Roth Capital affirms Applied Genetic Technologies (Nasdaq: AGTC) with a Buy rating and $34 price target after the company announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
